Sickle-Cell Trait: Novel Clinical Significance
Sickle-Cell Trait: Novel Clinical Significance
复制标题
DOI：
10.1182/asheducation-2010.1.418
复制
发表时间：
2010-12-01
影响因子：
3
通讯作者：
Derebail, Vimal K.
中科院分区：
文献类型：
--
作者：
Key, Nigel S.;Derebail, Vimal K.
关于镰状细胞性状（SCT）应被视为良性携带状态还是中间疾病表型，在文献中存在长期争议。由于SCT是新生儿镰状细胞病筛查的常规检测方法，因此必须就这一问题达成共识，以便为受影响的个人提供最佳医疗建议。新生儿后期的选择性筛查问题最近引起了人们的注意，因为全国大学生体育协会建议其成员学院和大学对学生运动员进行测试，以确认他们的携带者身份（如果还不知道的话）。该建议的既定目标是预防SCT运动员的运动相关猝死。我们回顾了一些报道的SCT并发症的新信息已经出现，特别是静脉血栓栓塞和肾脏表现。
There is a long-standing controversy in the literature as to whether sickle-cell trait (SCT) should be viewed as a benign carrier state or as an intermediate disease phenotype. Because SCT is routinely detected by neonatal screening for sickle-cell disease, it becomes imperative that consensus on this issue be achieved in order to provide the best medical advice to affected individuals. The issue of selective screening in the post-neonatal period was thrust into the limelight recently by the National Collegiate Athletic Association's recommendation that its member colleges and universities test student-athletes to confirm their carrier status if not already known. The stated goal of this recommendation was to prevent exercise-related sudden death in athletes with SCT. We review some of the reported complications of SCT for which new information has emerged, focusing particularly on venous thromboembolism and renal manifestations.